Topical modulation of interleukin-1 activity in corneal neovascularization

Cornea

Volumn 17, Issue 4, 1998, Pages 403-409

  Dana, M Reza ^a,b,c   Zhu, Su Ning ^a,c   Yamada, Jun ^a,c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Corneal neovascularization; Cytokine; Inflammation; Interleukin l; Interleukin 1 receptor antagonist

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANIMALS; CORNEAL NEOVASCULARIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; OPHTHALMIC SOLUTIONS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 0031782477     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003226-199807000-00011     Document Type: Article

References (58)

1. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;37:2485-94.
2. Klintworth GK, Burger PC. Neovascularization of the cornea: current concepts of its pathogenesis. Int Ophthalmol Clin 1983;23:27-39.
3. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization: pathogenesis and inhibition. Cornea 1987; 6:250-7.
4. Ey RC, Hughes WF, Bloome MA, Tallman CB. Prevention of corneal vascularization. Am J Ophthalmol 1968;66:1118-31.
5. Polack RM. Histopathological and histochemical alterations in the early stages of corneal graft rejection. J Exp Med 1962;116: 709-17.
6. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981;99:599-604.
7. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992;110:1392-403.
8. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A, The Collaborative Corneal Transplantation Studies Research Group. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 1994;101:1536-47.
9. Khodadoust AA. The allograft rejection reaction: the leading cause of late failure of clinical corneal grafts. CIVA Found Symp 1973;15:151-67.
10. Stulting RD, Sumers KD, Cavanagh HD, Waring GO III, Gammon JA. Penetrating keratoplasty in children. Ophthalmology 1984;91:1222-30.
11. Mader TH, Stulting RD. The high-risk penetrating keratoplasty. Ophthalmol Clin North Am 1991;4:411-26.
12. Bishop VL, Robinson LP, Wechsler AW, Billson FA. Corneal graft survival: a retrospective Australian study. Austr NZ J Ophthalmol 1986;14:133-8.
13. Volker-Dieben HJ, D'Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Austr NZ J Ophthalmol 1987;15:11-8.
14. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol 1990;48:191-226.
15. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ, on behalf of all contributing surgeons. Factors predictive of corneal graft survival: report from the Australian Corneal Graft Registry. Ophthalmology 1992;99:403-14.
16. Detmar M. Molecular regulation of angiogenesis in the skin [Editorial]. J Invest Dermatol 1996;106:207-8.
17. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267: 10931-41.
18. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-65.
19. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
20. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 1992;11:581-97.
21. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of interleukins. Arch Ophthalmol 1990;108:573-6.
22. Kijlstra A. The role of cytokines in ocular inflammation. Br J Ophthalmol 1994;78:885-6.
23. West-Mays JA, Strissel KJ, Sadow PM, Fini ME. Competence for collagenase gene expression by tissue fibroblasts requires activation of an interleukin 1 alpha autocrine loop. Proc Natl Acad Sci USA 1995;92:6768-72.
24. Staats HF, Lausch RN. Cytokine expression in vivo during murine herpetic stromal keratitis: effect of protective antibody therapy. J Immunol 1993;151:277-83.
25. Kennedy MC, Rosenbaum JT, Brown J, et al. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J Clin Invest 1995;95:82-8.
26. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40.
27. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antogonist. Nature 1990;343:341-6.
28. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
29. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
30. Hu DE, Hori Y, Presta M, Gresham GA, Fan TP. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation 1994;18:45-58.
31. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995;36: 2176-85.
32. Streilein JW, Bradley D, Sano Y, Sonoda Y. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci 1996;37:413-24.
33. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604-9.
34. Paciotti GF, Baron DJ, Licino JL, et al. Novel enzyme immunoassays for the detection of the cytokines interleukin 1a and interleukin 2 in the circulation of normal subjects: 24-hour profiles. Prog Neurol Endocrinol Immunol 1992;5:21-30.
35. Dana MR, Dai R, Zhu S, Yamada J, Streilein JW. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest Ophthalmol Vis Sci 1997;39:70-7.
36. Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation 1997;1501-7.
37. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
38. Barton K, Nava A, Monroy DC, Pflugfelder SC. Inflammatory cytokines and tear function in ocular surface disease. Adv Exp Med Biol (in press).
39. Bussolino F, Arese M, Montrucchio G, et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995;96:940-52.
40. Dethlefsen SM, Shepro D, D'Amore PA. Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp Cell Res 1994;212:262-73.
41. Cubitt CL, Lausch RN, Oakes JE. Differences in interleukin-6 gene expression between cultured human corneal epithelial cells and keratocytes. Invest Ophthalmol Vis Sci 1995;36:330-6.
42. Elner VM, Strieter RM, Pavilack MA, et al. Human corneal interleukin-8, IL-1 and TNF-induced gene expression and secretion. Am J Pathol 1991;139:977-88.
43. Tamura T, Nakanishi T, Kimura Y, et al. Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology 1996;137:3729-37.
44. Fukuo K, Inoue T, Morimoto S, et al. Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells: a possible mechanism of neovascularization in atherosclerotic plaques. J Clin Invest 1995;95:669-76.
45. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996;98:1667-75.
46. West-Mays JA, Sadow PM, Tobin TW, Strissel KJ, Cintron C, Fini ME. Repair phenotype in corneal fibroblasts is controlled by an interleukin-1 alpha autocrine feedback loop. Invest Ophthalmol Vis Sci 1997;38:1367-79.
47. Girard MT, Matsubara M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci 1991;32:2441-54.
48. 2, and proliferation in human fibroblasts. Exp Cell Res 1994;210:166-71.
49. Beck L Jr, D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997;11:365-73.
50. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
51. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
52. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995;270:308-12.
53. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
54. Corbacioglu S, Pietsch T, Koenig A, Weite K. Interleukin-1 receptor antagonist: a powerful inhibitor of tumor vascularization and tumor growth in vivo [Abstract]. Sixth International Symposium on Pediatric Neuro-Oncology 1994;35.
55. Fan TP, Hu DE, Guard S, Gresham GA, Watling KJ. Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol 1993;110:43-9.
56. Pflugfelder SC. Tear film influence on the ocular surface. Adv Exp Med Biol (in press).
57. Planck SR, Rich LF, Ansel JC, Huang XN, Rosenbaum JT. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocular Immunol Inflamm 1997;5: 95-100.
58. Raizman M. Corticosteroid therapy of eye disease: fifty years later. Arch Ophthalmol 1996;114:1000-1.